At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GH Guardant Health Inc.
Closed 06-12 16:00:00 EDT
131.62
+0.72
+0.55%
盘后131.84
+0.22+0.17%
19:58 EDT
High133.66Low128.50Vol1.51M
Open133.15D1 Closing130.90Amplitude3.94%
Mkt Cap17.45BTradable Cap16.72BTotal Shares132.57M
T/O198.51MT/O Rate1.19%Tradable Shares127.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00
Reuters  ·  04:27
Guardant Health CIO Kumud Kalia sells 5,000 common shares worth $652,030.00
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says
MT Newswires Live  ·  06-12 23:03
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says
RBC Initiates Guardant Health at Outperform With $185 Price Target
MT Newswires Live  ·  06-12 17:52
RBC Initiates Guardant Health at Outperform With $185 Price Target
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Reuters  ·  06-12 15:34
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Guardant Health Inc : RBC Initiates Coverage With Outperform Rating; Target Price $185
THOMSON REUTERS  ·  06-12 12:26
Guardant Health Inc : RBC Initiates Coverage With Outperform Rating; Target Price $185
BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte
Reuters  ·  06-11 21:13
BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte
Guardant Health Says FDA Approved Guardant360 CDx as Companion Diagnostic for Non-Small Cell Lung Cancer Therapy
MT Newswires Live  ·  06-11 20:39
Guardant Health Says FDA Approved Guardant360 CDx as Companion Diagnostic for Non-Small Cell Lung Cancer Therapy
BUZZ-Guardant Health rises as FDA clears blood test for lung cancer drug use
Reuters  ·  06-11 20:26
BUZZ-Guardant Health rises as FDA clears blood test for lung cancer drug use
Guardant Health announces U.S. FDA approved Guardant360 CDx
TIPRANKS  ·  06-11 20:21
Guardant Health announces U.S. FDA approved Guardant360 CDx
Guardant Health Announces FDA Approval of Guardant360 Cdx as Companion Diagnostic for Boehringer Ingelheim’s Hernexeos®
THOMSON REUTERS  ·  06-11 20:05
Guardant Health Announces FDA Approval of Guardant360 Cdx as Companion Diagnostic for Boehringer Ingelheim’s Hernexeos®
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?
Simply Wall St.  ·  06-10 13:13
Do GH Research’s (GHRS) Phase 2a Postpartum Data Subtly Reframe Its Broader Depression Strategy?
Guardant Health Co-CEO Helmy Eltoukhy disposes of common shares worth $12.54 million
Reuters  ·  06-09
Guardant Health Co-CEO Helmy Eltoukhy disposes of common shares worth $12.54 million
Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60
Reuters  ·  06-09
Guardant Health CFO Michael Brian Bell disposes of 2,000 common shares worth $257,240.60
Guardant Health Inc : Mizuho Raises Target Price to $175 From $135
THOMSON REUTERS  ·  06-08
Guardant Health Inc : Mizuho Raises Target Price to $175 From $135
Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million
Reuters  ·  06-06
Guardant Health director Steve Krognes disposes of 9,294 common shares worth $1.23 million
Guardant Health Initiated at Buy by Goldman Sachs
Dow Jones  ·  06-05
Guardant Health Initiated at Buy by Goldman Sachs
Guardant Health initiated with a Buy at Goldman Sachs
TIPRANKS  ·  06-05
Guardant Health initiated with a Buy at Goldman Sachs
Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)
TIPRANKS  ·  06-05
Leerink Partners Reaffirms Their Buy Rating on Guardant Health (GH)
Guardant Health director Meghan Verena Joyce reports disposal of common shares worth $1.27 million
Reuters  ·  06-05
Guardant Health director Meghan Verena Joyce reports disposal of common shares worth $1.27 million
A new blood test can help detect colon cancer, but it's not as good as the test you hate to take
Dow Jones  ·  06-05
A new blood test can help detect colon cancer, but it's not as good as the test you hate to take
No data available

Introduction

Company Name.
Guardant Health Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Issue price:
--